 | Up a level |
Van Mieghem, Nicolas M; Unverdorben, Martin; Hengstenberg, Christian; Möllmann, Helge; Mehran, Roxana; López-Otero, Diego; Nombela-Franco, Luis; Moreno, Raul; Nordbeck, Peter; Thiele, Holger; Lang, Irene; Zamorano, José L; Shawl, Fayaz; Yamamoto, Masanori; Watanabe, Yusuke; Hayashida, Kentaro; Hambrecht, Rainer; Meincke, Felix; Vranckx, Pascal; Jin, James; ... (2021). Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. The New England journal of medicine, 385(23), pp. 2150-2160. Massachusetts Medical Society 10.1056/NEJMoa2111016
Cohen, Alexander T; Hoffmann, Ulrich; Hainaut, Philippe; Gaine, Sean; Ay, Cihan; Coppens, Michiel; Schindewolf, Marc; Jimenez, David; Brüggenjürgen, Bernd; Levy, Pierre; Laeis, Petra; Fronk, Eva-Maria; Zierhut, Wolfgang; Malzer, Thomas; Manu, Marius Constantin; Reimitz, Paul-Egbert; Bramlage, Peter; Agnelli, Giancarlo (2020). ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries. European journal of internal medicine, 82, pp. 48-55. Elsevier 10.1016/j.ejim.2020.08.014
Agnelli, Giancarlo; Hoffmann, Ulrich; Hainaut, Philippe; Gaine, Sean; Ay, Cihan; Coppens, Michiel; Schindewolf, Marc; Jimenez, David; Brüggenjürgen, Bernd; Levy, Pierre; Laeis, Petra; Fronk, Eva-Maria; Zierhut, Wolfgang; Malzer, Thomas; Manu, Marius Constantin; Reimitz, Paul-Egbert; Bramlage, Peter; Cohen, Alexander T (2020). ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months. Thrombosis research, 196, pp. 297-304. Elsevier 10.1016/j.thromres.2020.09.001
